Fujirebio expands its Alzheimer’s disease test menu with the much awaited and fully automated Lumipulse^® G pTau 217 Plasma assay for Research Use Only (RUO)

“The launch of the pTau 217 Plasma assay on our fully automated LUMIPULSE platform is an essential step in the efforts of Fujirebio to bring novel, innovative neurodegenerative biomarkers to laboratories and clinicians around the world,” said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “Expectations are high for this new biomarker, and researchers and clinical research professionals can now study its clinical utility on a platform that has the required throughput and meets the regulatory requirements to support possible future routine use.”

About pTau 217

Current research indicates that plasma pTau, including pTau 217, is a predictor of amyloid status determined either by CSF¹ or PET², and therefore able to differentiate between Alzheimer’s disease (AD) and non-AD neurodegenerative diseases^3,4 and to predict progression to AD.^5,6 Blood-based biomarkers, such as plasma pTau, could potentially be used as inclusion criteria or to evaluate target engagement and treatment efficacy in clinical trials, and could further advance the development and implementation of disease-modifying treatments in the field of AD and related disorders.⁷ This assay is designed to measure specifically the phosphorylation on position threonine 217 in human plasma.

About Fujirebio

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products.

Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio remains the only company with such a comprehensive line-up of manual and fully automated neurodegenerative disease assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. More information can be found at www.fujirebio.com/alzheimer.

References:

1. Ashton N, et al. Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement, 19(5): 1913-1924, 2023.
2. Mielke M, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med, 28(7): 1398-1405, 2022.
3. Palmqvist S, et al. Discriminative accuracy of plasma phospho-tau 217 for Alzheimer’s disease vs other neurodegenerative disorders. JAMA, 324(8): 772-781, 2020.
4. Thijssen E, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol, 20(9): 739-752, 2021.
5. Jonaitis EM, et al. Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease. Brain Commun, 5(2): fcad057, 2023.
6. Mattsson-Carlgren N, et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol, 80(4): 360-369, 2023.
7. Gonzalez-Ortiz F, et al. Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications. Mol Neurodegener, 18(1): 18, 2023.